To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops

Alcon Research78 enrolled

Overview

This is a multi-site, randomized, investigator-masked study to evaluate the physical effects of Systane(R) versus Refresh Tears(R) in subjects with moderate to severe dry eye. It is a 6-week, perspective, randomized, active-controlled, investigator-masked, parallel group study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Dry Eye

Interventions

SystaneOTHER

Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)

Refresh TearsOTHER

Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient must be 18 years of age or older of any sex and any race, with a score of at least 2 (some of the time) on the subject-assessed Symptom Eligibility question. * A sodium fluorescein corneal staining sum of ≥ 3 in either eye. * A best-corrected visual acuity of 0.6 logMAR or better in each eye as assessed using an ETDRS chart. Exclusion Criteria: * A history or evidence of ocular or intraocular surgery in either eye within the past 6 months. * Lasik patients can be included if lasik surgery was greater than 6 months prior to the initiation of the study. * A history of intolerance or hypersensitivity to any component of the study medications.

Locations (1)

Vasan Eye Care Hospital

Saidāpet, Channai, India

Outcomes

Primary Outcomes

To evaluate physical effects of Systane and Refresh Tears in subjects to moderate to severe dry eye.

This is a descriptive study in which changes from baseline in Tear Break up Time, corneal staining, and the Ocular Symptoms Questionnaire will be evaluated by treatment group at every visit. The outcome of the IDEEL questionnaire at Visit 3 will be compared to Visit 1 by treatment group; the results of treatment satisfaction questionnaires will be tabulated by treatment at Visit 3.

Time frame: Baseline to visit 3 (Day 42)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.